LKLaszlo Kovacs

Laszlo Kovacs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laszlo Kovacs has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Podocan‐Like Protein 1 as a Novel Contributor to HIV‐Associated Pulmonary Vascular Disease

    by Laszlo Kovacs, Taylor C. Kress, Anita Kovacs‐Kasa, Robin Brice, Sakshi Vanjani, Rodger MacArthur, Coleton R. Jordan, Simone Kennard, Eric J. Belin de Chantemele

    Background: Thanks to the advent of combination antiretroviral therapy, life expectancy has noticeably increased in people with HIV; however, they also display an elevated susceptibility to developing severe pulmonary vascular disease. Despite efforts to understand the role of HIV‐encoded proteins in the pathogenesis of the disease, the underlying mechanisms remain to be elucidated. Methods: Using 3 mouse models of HIV and in vitro cell studies, we tested the hypothesis that HIV‐related proteins induce pulmonary vascular disease via Podnl1 (podocan‐like protein 1)‐dependent mechanisms. Results: We reported that the expression of HIV proteins in Tg26 mice and bone marrow transplant from Tg26 to wild‐type mice promotes the development of pulmonary vascular disease with no sex differences. RNAseq and quantitative polymerase chain reaction analysis revealed, for the first time, high expression of Podnl1 in the lungs of our HIV models. Strikingly, lung specimens from people with HIV on combination antiretroviral therapy exhibit higher Podnl1 levels compared with individuals without HIV. We also revealed that the observed cardiopulmonary alterations and expression levels of Podnl1 were more pronounced in aged intact Tg26 mice. In addition, Podnl1 overexpression resulted in increased collagen‐I production and pulmonary artery smooth muscle cells proliferation. Remarkably, we found that HIV‐Tat (transactivator of transcription) is the only viral protein detectable in peripheral blood mononuclear cells obtained from people with HIV on combination antiretroviral therapy, and chronic exposure of mice to HIV‐Tat recapitulated the cardiopulmonary complications of intact and bone marrow transplant Tg26 mice. Conclusions: We provide the first evidence that HIV‐Tat and Podnl1 are important contributing factors to pulmonary vascular disease related to HIV infection, which presents potential new therapeutic avenues for the prevention of HIV‐associated cardiopulmonary complications.

  • CD4 + T Cells Expressing Viral Proteins Induce HIV-Associated Endothelial Dysfunction and Hypertension Through Interleukin 1α–Mediated Increases in Endothelial NADPH Oxidase 1

    by Taylor C. Kress, Candee T. Barris, Laszlo Kovacs, Beryl N. Khakina, Coleton R. Jordan, Thiago Bruder-Nascimento, David W. Stepp, Rodger MacArthur, Vijay S. Patel, Jie Chen, et al.

    BACKGROUND: Although combination antiretroviral therapy has increased life expectancy in people living with HIV, it has led to a marked increase in the prevalence of hypertension, the cause of which is unknown. Despite combination antiretroviral therapy, HIV-derived proteins remain expressed and produced by CD4 + T lymphocytes in people living with HIV. However, their contribution to HIV-associated hypertension and impaired endothelium-dependent relaxation remains ill defined. METHODS: Here, we tested the hypothesis that CD4 + T cells expressing viral proteins contribute to endothelial dysfunction and hypertension using the Tg26 mouse model of HIV that expresses 7 of the 9 HIV proteins under the long terminal repeat promoter. We used male and female mice, bone marrow transplantation (BMT), adoptive transfer of CD4 + T cells, and aorta specimen discarded from people living with HIV. RESULTS: We reported that intact Tg26 mice and mice receiving BMT (Tg26→WT) or CD4 + T cells from Tg26 mice display impaired endothelium-dependent relaxation and hypertension. Conversely, BMT from WT mice into Tg26 mice, inhibition of T cell activation, and CD4 + T cell depletion restored endothelial function and blood pressure in Tg26 mice. Cytokine profiling revealed that Tg26 mice, Tg26→WT, and Tg26 CD4 + T cells consistently exhibit high interleukin 1α (IL-1α) levels with no significant increase in other cytokines, whereas BMT from WT mice into Tg26 mice reduced IL-1α levels. IL-1α neutralization reduced blood pressure and restored endothelial function in Tg26 mice. To investigate the role of CD4 + T cells and IL-1α in endothelial dysfunction, we developed an aorta-immune cell coculture system. Exposure of WT aortas to Tg26 CD4 + T cells impaired endothelium-dependent relaxation, which was blocked by IL-1α–neutralizing antibody. While investigating the mechanisms of endothelial dysfunction, we reported that Tg26 mice, Tg26→WT aorta exhibit high NADPH oxidase (NOX) 1 expression. IL-1α exposure increased NOX1 in human microvascular endothelial cells, and NOX1 blockade restored endothelial function in Tg26 and Tg26→WT arteries, whereas NOX1 deficiency protected against Tg26 BMT-induced impaired endothelium-dependent relaxation and hypertension. Aortas from people living with HIV exhibit high NOX1 levels, and exposure of human aorta to Tg26 T cells increased NOX1 expression. CONCLUSIONS: We provide the first evidence that CD4 + T cells expressing HIV viral proteins induced hypertension through IL-1α–mediated increases in vascular NOX1, which impairs endothelial function in males and females.


  • Open Access

    A háziorvos szerepe az acromegaliás betegek gondozásában, fókuszban a szénhidrát-anyagcsere zavara

    by Csenge Hargittay, Judit Dénes, Erika Hubina, Gábor László Kovács, Zoltán Görömbey, Sándor Czirják, László Kovács, Krisztián Vörös, Miklós Góth

    Az acromegalia ritka, de klinikailag fontos betegség, amelyet a növekedési hormon és az inzulinszerű növekedési faktor-1 krónikusan magas szintje okoz. Számos tünete és komplikációja lehet, amelyek közül a diabetes mellitus gyakori szövődmény. A növekedési hormon különböző mechanizmusokon keresztül hathat a szénhidrát-anyagcserére és idézhet elő inzulinrezisztenciát. Cikkünkben egy acromegaliás beteg esetét dolgozzuk fel, kiemelve a beteg szénhidrátanyagcsere-eltéréseit, valamint az eset kapcsán ismertetjük az acromegalia kezelésében használt terápiás lehetőségeknek a glükózháztartásra gyakorolt hatását a nemzetközi irodalom áttekintésével. A contrainsularis hatású növekedésihormon-túlprodukció rontja a glükóztoleranciát. Ennek megfelelően a kórosan fokozott növekedésihormon-termelést csökkentő különböző kezelési módok (mint a sebészi vagy radioterápia, illetve a gyógyszeres kezelés bizonyos típusai) hatására javul a szénhidrát-anyagcsere. Ugyanakkor a gyógyszeres terápiás lehetőségek közül az első generációs szomatosztatinreceptor-ligandok az esetek kis részében ronthatják a szénhidrátháztartást, míg a második generációs pazireotid a betegek jelentős részénél hyperglykaemiát okoz. Az acromegaliás beteg kezelése komplex feladat, több diszciplína képviselői (endokrinológus, idegsebész, radioterapeuta, az egyes speciális problémák megoldásában részt vevő orvosok, fogorvosok) végzik, de a kezelés összefogásáért az endokrinológus szakorvos a felelős. Az acromegaliának, illetve a kezelés szövődményeinek, kiemelten a szénhidrátháztartás zavarainak ellátásában a háziorvosnak is fontos szerepe van, ehhez pedig ismernie kell a kezelési módozatok főbb pontjait és potenciális mellékhatásait. Orv Hetil. 2020; 161(40): 1724–1729.


  • Preoperative Flap Volume Prediction in Autologous Abdominal Breast Reconstruction

    by Maximilian Eder, Stefan Raith, Jalil M.Sc. Jalali, Laszlo Ph.D. Kovacs